Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 02:15PM GMT
Release Date Price: $9.18 (-1.82%)
Ashwin Pai;Morgan Stanley;Managing Director

Good morning, everyone, and thank you for joining us for the fireside chat for Sangamo Therapeutics. A quick note before we get started. For important disclosures, please see the Morgan Stanley research disclosure website at www.morganstanley.com/researchdisclosures. If you have any questions, please reach out to your Morgan Stanley sales representative.

Very pleased this morning to be joined by the CEO of Sangamo, Sandy Macrae. And Sandy, I'll turn it over to you. And perhaps we can maybe just get a brief overview of Sangamo before we start talking, going into some Q&A.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Good morning, Ashwin, and thank you for introducing me, and it's a pleasure to be here with Morgan Stanley. And it's a pleasure to present Sangamo Therapeutics. Sangamo is a fascinating company. It's a genomic medicines company with 3 medicines

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot